The impact of carvedilol and metoprolol on serum lipid concentrations and symptoms in patients with hyperthyroidism

Endocrine Research

Volumn 37, Issue 3, 2012, Pages 117-123

  Ozbilen, Sabahattin ^a   Eren, Mehmet Ali ^a   Turan, Mehmet Nuri ^a   Sabuncu, Tevfik ^a  

^a HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Carvedilol; Dyslipidemia; Hypertension; Hyperthyroidism; Metoprolol; Triglyceride

Indexed keywords

CARVEDILOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIOTHYRONINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEART RATE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; SYMPTOM; SYSTOLIC BLOOD PRESSURE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BLOOD PRESSURE; CARBAZOLES; HEART RATE; HUMANS; HYPERTENSION; HYPERTHYROIDISM; LIPIDS; METOPROLOL; MIDDLE AGED; PROPANOLAMINES; THYROTROPIN; THYROXINE;

EID: 84863454677     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2011.643436     Document Type: Article

References (34)

1. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol 2007;49:71-81.
2. Iglesias P, Dévora O, García J, Tajada P, García-Arévalo C, Díez JJ. Severe hyperthyroidism: aetiology, clinical features and treatment outcome. Clin Endocrinol (Oxf) 2010;72(4):551-557.
3. Cooper DS. Hyperthyroidism. Lancet 2003;362:459-468.
4. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006;35:663-686.
5. Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens (Greenwich) 2006;8(8):596-599.
6. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000;13(1):3-10.
7. Nayak B, Hodak SP. Hyperthyroidism. Endocrinol Metab Clin North Am 2007;36:617-656.
8. Cruickshank JM. Beta-blockers, plasma lipids, and coronary heart disease. Circulation 1990;82: 60-65.
9. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133-141.
10. Rabkin SW, Huff MW, Newman C, Sim D, Carruthers SG. Lipids and lipoproteins during antihyper-tensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension 1994;24:241-248.
11. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;45:232-258.
12. Uzunlulu M, Oguz A, Yorulmaz E. The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. Int Heart J 2006;47:421-430.
13. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab 2009;11:234-238.
14. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-959.
15. Sanderson JE, Leung LY, Chan SK, Yip GW, Fung JW, Yu CM. Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure? Eur J Heart Fail 2005;7(5):874-877.
16. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116:1725-1735.
17. Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens (Greenwich) 2006;8:596-599.
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
19. Zhang GQ, Zhang W. Heart rate, lifespan, and mortality risk. Ageing Res Rev 2009;8:52-60.
20. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol versus meto-prolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007;20:777-783.
21. Liberopoulos EN, Elisaf MS. Dyslipidemia in patients with thyroid disorders. Hormones (Athens) 2002;1(4):218-223.
22. Kung AW, Pang RW, Lauder I, Lam KS, Janus ED. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem 1995;41:226-231.
23. Cachefo A, Boucher P, Vidon C, Dusserre E, Diraison F, Beylot M. Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients. J Clin Endocrinol Metab 2001;86:5353-5357.
24. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133-141.
25. Diekman MJ, Anghelescu N, Endert E, Bakker O, Wiersinga WM. Changes in plasma low-density lipoprotein (LDL)-and high-density lipoprotein cholesterol in hypo-and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes. J Clin Endocrinol Metab 2000;85:1857-1862.
26. Nikkilä EA, Kekki M. Plasma triglyceride metabolism in thyroid disease. J Clin Invest 1972;51: 2103-2114.
27. Lehtonen A. Effects of beta-blockers on plasma lipids during antihypertensive therapy. J Cardiovasc Pharmacol 1985;7:110-114.
28. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000;139:174-183.
29. Sharp RP, Sirajuddin R, Sharief IM. Impact of carvedilol on the serum lipid profile. Ann Pharma-cother 2008;42:564-571.
30. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292: 2227-2236.
31. Seguchi H, Nakamura H, Aosaki N, Homma Y, Mikami Y, Takahashi S. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol 1990;38:139-142.
32. Goto Y, Tamachi H, Fusegawa Y, et al. Effects of carvedilol on serum lipids in patients with essential hypertension. J Cardiovasc Pharmacol 1991;18:45-50.
33. Bhatt P, Makwana D, Santani D, Goyal R. Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with L-thyroxin-induced hyperthyroidism\an experimental study. Can J Physiol Pharmacol 2007;85:514-520.
34. Chapman N, Chang CL, Dahlöf B, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008;118:42-48.